[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368109-105":59,"doc-detail-368109-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","clinical-validation-of-a-multi-model-blood-cfdna-methylation-assay-for-early-stage-gastrointestinal-cancer-screening","Clinical validation of a multi-model blood cfDNA methylation assay for early-stage gastrointestinal cancer screening","","Gastrointestinal tract cancers remain a major cause of cancer-related death, largely driven by late diagnosis. This study develops SPOGIT, a blood-based cfDNA methylation screening method optimized for early-stage gastrointestinal cancer and precancer detection, integrating multiple algorithms. SPOGIT is built using large-scale public tissue methylation data and cfDNA methylation probe profiles, then validated internally and across multiple centers. Results show high overall diagnostic accuracy with strong sensitivity for early-stage disease, plus performance for adenomas and gastric precancerous lesions, supported by an interception potential. A complementary CSO model aids localization, while simulations estimate fewer late-stage diagnoses and improved 5-year survival.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-validation-of-a-multi-model-blood-cfdna-methylation-assay-for-early-stage-gastrointestinal-cancer-screening/368109/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-validation-of-a-multi-model-blood-cfdna-methylation-assay-for-early-stage-gastrointestinal-cancer-screening/368109.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is SPOGIT and what does it target?","Question",{"text":113,"@type":114},"SPOGIT is a blood-based cfDNA methylation screening approach designed to detect early-stage gastrointestinal cancers and precancerous lesions. It is optimized for population-level screening and timely clinical intervention.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was SPOGIT validated in the study?",{"text":118,"@type":114},"SPOGIT underwent rigorous validation using an internal set and an external multicenter cohort. An interception model was also used to assess clinical potential.",{"name":120,"@type":111,"acceptedAnswer":121},"What performance did SPOGIT show for early-stage and precancer detection?",{"text":122,"@type":114},"SPOGIT achieved high overall diagnostic accuracy, with reported sensitivity of 88.1% and specificity of 91.2%. It also showed sensitivity for early-stage (0–II) cancers and performance for advanced adenomas and gastric precancerous lesions.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368109,1790578860,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Journal of Advanced Research 85 (2026) 389–401  \nContents lists available at ScienceDirect  \nJournal of Advanced Research  \njournal [homepage: www. elsevier. com/locate/jare](homepage: www. elsevier. com/locate/jare)  \nClinical validation of a multi-model blood cfDNA methylation assay for early-stage gastrointestinal cancer screening  \nLingqin Zhu a,b, 1, Shuye Lin a,b, 1, Junfeng Xu c,d, 1, Jianwei Yu e, Fangli Men f, Dongliang Yu c,d, Xianzong Mad, Ju Tian g, Hui Xied, Linghui Duand, Xin Wang d, Shuyang Sun a,b, Chenguang Li a,b, Shu Li a,b, Qian Kang a,b, Mengyu Jiaf, Xueqin Lin e, Qiaoqiao Lin e, Lijuan Lin e, Xiang Yi h, Ruiru Wang h, Wei Guoh, Xueqing Gong h, Jianqiu Sheng c,d, Ni Guo f,⁎, Shiqian Lan e,⁎, Peng Jin c,d,⁎⁎, Yuqi He a,b,⁎⁎⁎  \na Department of Gastroenterology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China b Laboratory for Clinical Medicine, Capital Medical University, Beijing 101149, China  \nc Senior Department of Gastroenterology, The First Medical Center of Chinese People’s Liberation Army General Hospital, No. 28 of Fuxing Road, Haidian District, Beijing 100853, China d Department of Gastroenterology, Seventh Medical Center of Chinese PLA General Hospital, No.5 Nanmencang, Dongcheng District, Beijing 100700, China  \ne Department of Gastroenterology, Longyan First Afﬁliated Hospital of Fujian Medical University, 105 Jiuyi Road (North), Longyan 364000, China f Department of Gastroenterology, Dongying People’s Hospital, Nan Yi Lu 317, Dongying District, Dongying 257000, China  \ng Department of Hepatobiliary and Pancreatic Surgery, The First Medical Center of Chinese PLA General Hospital, Institute of Hepatobiliary Surgery and Key Laboratory of Digital Hepetobiliary Surgery of Chinese PLA General Hospitall, No. 28 of Fuxing Road, Haidian District, Beijing 100853, China  \nh Shanghai Yingce Biotechnology Co., Ltd, Room 202, 203, 2nd Floor, No. 4, Lane 288, Mingnan Road, Songjiang District, Shanghai 201613, China  \nh i g h l i g h t s  \n• High Accuracy: SPOGIT was demonstrated robust performance in multicenter validation set (88. 1 % sensitivity, 91.2 % speciﬁcity, n = 1,079).  \n• Early Detection: The sensitivities of AA, high-risk preGC and low-risk preGC were 56.5 %, 62.4 % and 49.5 % respectively.  \n• Better Outcomes: SPOGIT may reduce late-stage diagnoses by 92 % and boost 5-year survival rates by 27.02– 30.47 %, enabling earlier intervention.  \n• Minimally Invasive & Accessible: Requires only 10 mL of blood and \u003C30 ng cfDNA input, ideal for lowresource healthcare settings.  \ng r a p h i c a l a b s t r a c t  \na r t i c l e i n f o  \nArticle history:  \nReceived 17 July 2025  \nRevised 30 September 2025 Accepted 20 October 2025 Available online 24 October 2025  \na b s t r a c t  \nBackground: Gastrointestinal (GI) tract cancers are the second leading cause of cancer-related mortality, often due to late detection. There is a critical need for non-invasive, highly sensitive biomarkers for earlystage cancer and precancerous lesion detection to enable timely intervention. This study aimed to develop a blood-based method speciﬁcally optimized for early GI cancer detection and populationlevel screening.  \n⁎ Corresponding authors.  \n⁎⁎ Corresponding author at: Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Beijing, China.⁎⁎⁎ Corresponding author at: Department of Gastroenterology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China.  \nE-mail addresses: [guoni1974@sina.com](guoni1974@sina.com) (N. Guo), [lan4000@163.com](lan4000@163.com) (S. Lan), [jinpeng@301hospital.com.cn](jinpeng@301hospital.com.cn) (P. Jin), [endohe@163.com](endohe@163.com) (Y. He).  \n1 These authors contributed equally to this work.  \n[https://doi.org/10.1016/j.jare.2025.10.0","cbCairYyavBegppO","https://ap.wps.com/l/cbCairYyavBegppO","pdf",3356265,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What is SPOGIT and what does it target?\",\"answer\":\"SPOGIT is a blood-based cfDNA methylation screening approach designed to detect early-stage gastrointestinal cancers and precancerous lesions. It is optimized for population-level screening and timely clinical intervention.\"},{\"question\":\"How was SPOGIT validated in the study?\",\"answer\":\"SPOGIT underwent rigorous validation using an internal set and an external multicenter cohort. An interception model was also used to assess clinical potential.\"},{\"question\":\"What performance did SPOGIT show for early-stage and precancer detection?\",\"answer\":\"SPOGIT achieved high overall diagnostic accuracy, with reported sensitivity of 88.1% and specificity of 91.2%. It also showed sensitivity for early-stage (0–II) cancers and performance for advanced adenomas and gastric precancerous lesions.\"}]","Clinical validation of a multi-model blood cfDNA methylation assay for early-stage gastrointestinal cancer screening | PDF",1790175035,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a58dcf2096c392b3c24f5c411ba3d27.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d28a21e3a207b9af5cf7af8c2d5defd4.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f8e29073fb0322179466eb2b3be8fc1.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b791bceb24fafa63438803d52f5e60b9.webp",980,1306]